novo nordisk semaglutide alzheimer trial Semaglutide's Alzheimer's Failure: Rethinking Molecular Targets Beyond Amyloid AD/PD 2026: Novo Nordisk's semaglutide

Immediate medical attention is required

Some women experience temporary nausea, flushing, or a headache shortly after using the spray

Miamis humidity maintains skin moisture during healing, which is beneficial, but the heat and bacterial environment require extra care to prevent contamination of the treatment area during the first 72 hours

Commercial Development: In August 2025, Jocasta Neuroscience raised $35 million in Series A funding to advance JN-0413, a proprietary -klotho formulation, through Phase 1 trials with IND submission planned for Q4 2026

The expected launch of Mazdutide will be the first domestic GLP-1 medicine with indications for both obesity and diabetes